{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=IBD&page=17",
    "query": {
      "condition": "IBD",
      "page": 17
    },
    "page_size": 10
  },
  "pagination": {
    "page": 17,
    "page_size": 10,
    "total_count": 1553,
    "total_pages": 156,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=IBD&page=18&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=IBD&page=16&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-22T08:30:58.464Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06249555",
      "title": "VOICE-Early Response to Vedolizumab and IL-23 Antagonists in Participants With Crohn's Disease: A Prospective Observational Study",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Crohn's Disease"
      ],
      "interventions": [
        {
          "name": "Vedolizumab (VDZ)",
          "type": "DRUG"
        },
        {
          "name": "Ustekinumab (UST)",
          "type": "DRUG"
        },
        {
          "name": "Risankizumab (RISA)",
          "type": "DRUG"
        },
        {
          "name": "Guselkumab (GUS)",
          "type": "DRUG"
        },
        {
          "name": "Mirikizumab (MIR)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alimentiv Inc.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 300,
      "start_date": "2024-03-20",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2026-08-21",
      "last_synced_at": "2026-10-22T08:30:58.464Z",
      "location_count": 11,
      "location_summary": "Sun City, Arizona • Evanston, Illinois • Iowa City, Iowa + 8 more",
      "locations": [
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "Evanston",
          "state": "Illinois"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        },
        {
          "city": "Chestnut Hill",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06249555"
    },
    {
      "nct_id": "NCT01586533",
      "title": "Study of the Safety and Efficacy of Zoenasa® Versus Mesalamine Enema in Subjects With Left-Sided Ulcerative Colitis",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ulcerative Colitis",
        "Left-sided Ulcerative Colitis",
        "Distal Ulcerative Colitis"
      ],
      "interventions": [
        {
          "name": "Zoenasa-1:4",
          "type": "DRUG"
        },
        {
          "name": "Mesalamine Enema",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Altheus Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 120,
      "start_date": "2012-06",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2014-01-08",
      "last_synced_at": "2026-10-22T08:30:58.464Z",
      "location_count": 45,
      "location_summary": "Birmingham, Alabama • Dothan, Alabama • Lakewood, Colorado + 39 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Lakewood",
          "state": "Colorado"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Hialeah",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01586533"
    },
    {
      "nct_id": "NCT01020708",
      "title": "Study of the Safety and Tolerability of ALTH12 Versus Mesalamine Enema in Subjects With Left-Sided Ulcerative Colitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Ulcerative Colitis"
      ],
      "interventions": [
        {
          "name": "mesalamine",
          "type": "DRUG"
        },
        {
          "name": "ALTH12-1:4",
          "type": "DRUG"
        },
        {
          "name": "ALTH12-2:4",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Altheus Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 9,
      "start_date": "2009-11",
      "completion_date": "2010-09",
      "has_results": false,
      "last_update_posted_date": "2011-03-29",
      "last_synced_at": "2026-10-22T08:30:58.464Z",
      "location_count": 1,
      "location_summary": "Oklahoma City, Oklahoma",
      "locations": [
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01020708"
    },
    {
      "nct_id": "NCT00552058",
      "title": "Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Remission in Patients With Crohn's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Crohn Disease"
      ],
      "interventions": [
        {
          "name": "certolizumab pegol (CDP870, CZP)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "UCB Pharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 439,
      "start_date": "2008-03",
      "completion_date": "2009-11",
      "has_results": true,
      "last_update_posted_date": "2018-08-09",
      "last_synced_at": "2026-10-22T08:30:58.464Z",
      "location_count": 24,
      "location_summary": "Pell City, Alabama • Colorado Springs, Colorado • Lakewood, Colorado + 21 more",
      "locations": [
        {
          "city": "Pell City",
          "state": "Alabama"
        },
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        },
        {
          "city": "Lakewood",
          "state": "Colorado"
        },
        {
          "city": "Littleton",
          "state": "Colorado"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00552058"
    },
    {
      "nct_id": "NCT03558048",
      "title": "The Effect of IBD Flares on Serum PSA",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Inflammatory Bowel Diseases",
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Blood draw",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Northwestern University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "69 Years",
        "sex": "MALE",
        "summary": "40 Years to 69 Years · Male only"
      },
      "enrollment_count": 400,
      "start_date": "2019-08-01",
      "completion_date": "2025-10-01",
      "has_results": false,
      "last_update_posted_date": "2024-04-24",
      "last_synced_at": "2026-10-22T08:30:58.464Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03558048"
    },
    {
      "nct_id": "NCT04114292",
      "title": "TUDCA as a Therapy for Ulcerative Colitis (UC)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Ulcerative Colitis"
      ],
      "interventions": [
        {
          "name": "Tauroursoursodeoxycholic acid, brand name Tudcabil",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 14,
      "start_date": "2019-01-17",
      "completion_date": "2022-06-07",
      "has_results": false,
      "last_update_posted_date": "2026-03-10",
      "last_synced_at": "2026-10-22T08:30:58.464Z",
      "location_count": 3,
      "location_summary": "Creve Coeur, Missouri • St Louis, Missouri",
      "locations": [
        {
          "city": "Creve Coeur",
          "state": "Missouri"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04114292"
    },
    {
      "nct_id": "NCT04131504",
      "title": "Precision Crohn's Disease Management Utilizing Predictive Protein Panels (ENvISION)",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Crohn's Disease",
        "IBD"
      ],
      "interventions": [
        {
          "name": "Infliximab",
          "type": "DRUG"
        },
        {
          "name": "Adalimumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Children's Hospital Medical Center, Cincinnati",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "22 Years",
        "sex": "ALL",
        "summary": "1 Year to 22 Years"
      },
      "enrollment_count": 239,
      "start_date": "2019-10-16",
      "completion_date": "2023-10-31",
      "has_results": false,
      "last_update_posted_date": "2024-01-30",
      "last_synced_at": "2026-10-22T08:30:58.464Z",
      "location_count": 4,
      "location_summary": "Hartford, Connecticut • Cincinnati, Ohio • Columbus, Ohio + 1 more",
      "locations": [
        {
          "city": "Hartford",
          "state": "Connecticut"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04131504"
    },
    {
      "nct_id": "NCT03729271",
      "title": "Hydrogen Breath Test an Instrument to Predict Rifaximin-Response in Irritable Bowel Syndrome Predominant Diarrhea",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Irritable Bowel Syndrome",
        "Irritable Bowel Syndrome With Diarrhea"
      ],
      "interventions": [
        {
          "name": "Rifaximin",
          "type": "DRUG"
        },
        {
          "name": "Glucose and lactulose hydrogen breath testing",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "University of Michigan",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 148,
      "start_date": "2020-01-09",
      "completion_date": "2026-01-01",
      "has_results": false,
      "last_update_posted_date": "2026-01-12",
      "last_synced_at": "2026-10-22T08:30:58.464Z",
      "location_count": 1,
      "location_summary": "Ann Arbor, Michigan",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03729271"
    },
    {
      "nct_id": "NCT00438711",
      "title": "Surgical Decision Making Among People With Inflammatory Bowel Disease",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Inflammatory Bowel Disease"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "University of North Carolina, Chapel Hill",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 91,
      "start_date": "2005-09",
      "completion_date": "2008-12",
      "has_results": false,
      "last_update_posted_date": "2017-11-17",
      "last_synced_at": "2026-10-22T08:30:58.464Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00438711"
    },
    {
      "nct_id": "NCT04655599",
      "title": "Effect of Olorinab on Gastrointestinal Transit in Patients With Irritable Bowel Syndrome",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Irritable Bowel Syndrome"
      ],
      "interventions": [
        {
          "name": "Olorinab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Arena Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 1,
      "start_date": "2021-01-29",
      "completion_date": "2021-04-13",
      "has_results": false,
      "last_update_posted_date": "2021-05-17",
      "last_synced_at": "2026-10-22T08:30:58.464Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04655599"
    }
  ]
}